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Gene Reporter Assay to Validate MicroRNA  
Targets in Drosophila S2 Cells
Bünyamin Akgül and Çag˘das¸ Göktas¸
Abstract
Bioinformatics programs have helped tremendously in identifying the targets of microRNAs, which are 
small noncoding RNAs that regulate gene expression posttranscriptionally. However, the partial comple-
mentarity between miRNAs and their targets hinders the accuracy of target prediction, necessitating the 
use of experimental validation procedures. Here, we describe a gene reporter assay typically used in our lab 
to validate putative miRNA–mRNA interactions in Drosophila S2 cells.
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1 Introduction
MicroRNAs (miRNAs) are small noncoding RNAs of 17–25 
nucleotides in length that posttranscriptionally regulate gene 
expression by perfectly or imperfectly base pairing with their target 
mRNAs in plants and animals, respectively [1, 2]. MicroRNAs are 
involved in a number of fundamental cellular processes ranging 
from metabolism to cell growth and differentiation to apoptosis 
[3–5]. The current estimate is that over half of the mammalian 
protein-coding genes are controlled posttranscriptionally through 
various mechanisms by miRNAs [6]. A single miRNA can regulate 
the expression of multiple target genes, but at the same time, one 
target gene can be independently or cooperatively regulated by 
multiple miRNAs.
Advances in sequencing technology have led to a great prog-
ress in the identification of novel miRNAs in a wide range of spe-
cies [7–9]. This has been further supplemented with sophisticated 
target prediction algorithms to effectively predict miRNA–mRNA 
interactions [10–13]. Since the base pairing between miRNAs and 
their targets is imperfect in animals, the interactions predicted by 
bioinformatics tools have to be validated experimentally to avoid 
potential false-positive target predictions.
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A number of different approaches have been used in the 
 experimental identification of putative miRNA–mRNA interac-
tions [14, 15]. Broadly, these approaches have been categorized 
under transcriptome analyses, biochemical approaches, and pro-
teome analyses. The choice primarily depends upon the intended 
number of targets. For example, if the aim is to identify multiple 
miRNA targets at once, a genomics approach such as transcrip-
tome or proteome analyses, following miRNA knockdown or over-
expression, would be highly desirable. The handicap of this 
approach is that it would be cumbersome to distinguish between 
direct or indirect effects of miRNAs on target expression. To avoid 
indirect miRNA effects in a genomics target screen, AGO or RISC 
immunoprecipitation can be combined with microarray or deep-
sequencing analysis of total RNA isolated from the immunopre-
cipitate in the presence and absence of an miRNA of interest 
([16, 17], Chapter 6). By doing so, the changes in the mRNA 
contents, thus miRNA targets, of RISC complexes can be directly 
identified when miRNAs are over-expressed or knocked-down.
Direct demonstration of miRNA targets usually involves experi-
mental identification of target mRNAs individually. This approach 
nicely eliminates indirect off-target effects since the function of the 
reporter mRNA is determined exclusively by a physical interaction 
between the miRNA of interest and the reporter construct. One dis-
advantage of this approach is that it is quite labor-intensive. The 
results should still be interpreted carefully especially when miRNAs 
are over-expressed transiently. Any superficial increase in the intracel-
lular miRNA concentration beyond its physiological concentration 
could potentially generate false-positive results by interfering with 
the interaction between other miRNAs and RISC complexes [18].
In this chapter, a gene reporter assay is described in which the 
3′UTR of a target mRNA is cloned into an expression vector bear-
ing a reporter gene (e.g., luciferase). When co-expressed with the 
miRNA, the miRNA-mediated suppression of the reporter func-
tion, miRNA:target interaction, can easily be measured. Cells with-
out miRNA are used as negative controls. Additionally, constructs 
containing 3′UTRs with mutated target sites serve as additional 
negative controls. This approach can be further solidified by using 
miRNA inhibitors in the experimental design.
2 Materials
●● PCR Cloning Kit (Fermentase InsTAclone™ PCR cloning kit 
#K1213 which contains the TA cloning vector pTZ57R/T, 5× 
ligation buffer, T4 DNA ligase and nuclease-free water).
●● Fragment isolation kit (Invitrogen PureLink gel extraction kit, 
K2100-12).
2.1 Molecular 
Cloning Components
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●● Plasmid purification Kits (Fermentas GeneJET™ plasmid miniprep 
kit K0503; Invitrogen PureLink™ HiPure plasmid filter midi-
prep kit K2100-15).
●● Restriction enzymes.
●● Taq DNA polymerase (Fermentas).
●● Squishing buffer (10 mM Tris–Cl, pH 8.2, 1 mM EDTA, 
25 mM NaCl, and 200 μg/ml proteinase K).
●● SOC medium (0.5 % yeast extract, 2 % Tryptone, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
glucose).
●● Schneider’s Drosophila medium (Invitrogen 11720-034).
●● Heat inactivated fetal bovine serum (Invitrogen, GIBCO 
10500).
●● Penicillin G (Biochrom AG, A321-44), Streptomycin (Biochrom 
AG, A331-44).
●● Calcium-phosphate transfection kit (Invitrogen K2780-01), 
(2× HEPES-buffered saline (HBS), 2 M CaCl2, tissue culture 
sterile water).
Drosophila Schneider 2 embryonic stem cells are maintained 
in Drosophila Schneider medium (Invitrogen) supplemented with 
l-Glutamine, 10 % FBS (GIBCO) and 2 % Penicillin–Streptomycin 
(Biochrom AG) at 25 °C without CO2. Passages of cells are per-
formed twice a week.
●● Luciferase assay kit (Promega, E1960).
●● Passive cell lysis buffer (glycerol (50–75 %), CDTA (1.0–5.0 %), 
N,N-Bis(3-d-glukonamidopropyl) cholamide (<1.00 %)).
●● 1× PBS [(1) 8 g NaCl, (2) 0.2 g KCl, (3) 1.44 g Na2HPO4, (4) 
0.24 g KH2PO4, (5) in 800 ml of distilled H2O, (6) adjust the 
pH to 7.4 with HCl. Add H2O to 1 l].
3 Methods
Three main constructs should be prepared to perform a complete 
luciferase dual reporter assay. The first construct contains the 
miRNA precursor, which is expressed under the control of a potent 
promoter such as actin. The second one is a chimeric construct 
carrying the open reading frame of the luciferase firefly gene fused 
to the 3′UTR of the target mRNA of interest. The third construct 
carries the luciferase renilla which is used to normalize the transfec-
tion efficiency.
2.2 S2 Cell 
Maintenance  
and Transfection 
Components
2.3 Luciferase Assay 
Components
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There are at least three different ways of over expressing miRNAs 
in cell lines such as Drosophila S2 cells. Several commercial com-
panies provide experimentally validated synthetic mature miRNAs 
or their precursors (pre-miRNA). Transient transfection of these 
molecules is easy and quick but requires dose kinetics to determine 
expression levels comparable to their endogenous concentrations 
in the cell line used. The third approach involves the expression of 
miRNAs on an expression vector carrying a strong promoter. The 
use of an inducible promoter would be desirable, if possible, to 
modulate the expression levels of miRNA transcripts. In this sec-
tion, the third approach will be described.
The cloning of an miRNA gene into an expression vector can be 
carried out in two ways. In the first option, the PCR-amplified 
miRNA sequence is directly cloned into the expression vector. This 
approach saves time by eliminating a second cloning step. However, 
the preparation of the fragments and the vector carrying the match-
ing restriction sites can be difficult especially for beginners. In this 
situation, it may be easier to clone the miRNA sequence into a TA 
cloning vector such as pTZ57R/T (Fermentase). The fragment can 
then be easily transferred from this sub-cloning vector into the 
expression vector. Unless specified by the product provider, the pro-
tocols described by Sambrook and Russell are usually followed [19].
Although the isolation procedure may vary depending upon the 
cell/tissue, singly fly genomic DNA isolation procedure [20] was 
used to prepare the genomic DNA for PCR amplification of the 
miRNA precursor. The same protocol was applied to isolate 
genomic DNA from S2 cells. The following procedure has given 
excellent results especially with Drosophila embryos or adult flies.
 (a) A single fly is mashed five to ten times by a pipet tip in 100 μl 
squishing buffer.
 (b) The mixture is incubated at 37 °C for 30 min following the 
addition of proteinase K (200 μg/ml). The powder proteinase 
K should be dissolved in pure water, divided in aliquots, and 
stored at −20 °C until use to minimize the loss of activity.
 (c) Proteinase K is then inactivated by heating the sample at 95 °C 
for 2 min. As an option, RNAse can be added to the mixture 
followed by phenol–chloroform extraction to eliminate con-
taminating RNAs. Usually, RNA should not interfere with 
DNA amplification, though. The genomic DNA can be stored 
at −20 °C until use.
 (d) Forward and reverse primers are designed to amplify candidate 
miRNA precursors by PCR. An example is presented in Fig. 1. 
Both forward and reverse primers can be about 20–25 nucleo-
tides in length. A restriction enzyme recognition site should be 
placed on the 5′-ends of primers to facilitate cloning in the 
subsequent steps. Having the same restriction site on both 
primers makes it easy to prepare the fragments for cloning. 
3.1 MicroRNA 
Overexpression 
Constructs
3.1.1 PCR Amplification 
of an MicroRNA Gene from 
Genomic DNA and Cloning 
into Expression Vectors
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However, the fragment can be cloned in either orientation, 
which requires verification of the correct orientation. To avoid 
this problem, different restriction sites should be placed on 
each primer. The selected restriction sites should be present 
only in the multiple cloning site of the expression vector and 
absent in the other regions of the vector or the candidate 
miRNA gene. Such non-cuter sites can be detected by pro-
grams freely available on the web (e.g., RESTRICTION 
MAPPER: http://www.restrictionmapper.org/). Primers are 
designed to amplify at least a region 150–200 bp flanking from 
each side of the mature miRNA sequence.
 (e) PCR amplification may require optimization of the annealing 
temperature and the template amount but the setup described 
below may be a good start. Mix the following in a clean 
Eppendorf tube: 2.5 μl 10× taq buffer (Fermentase), 1.5 μl 
25 mM MgCl2, 0.5 μl 10 mM dNTP mix (Fermentase), for-
ward primer (5–10 mM), reverse primer (5–10 mM), 0.75–1 
unit Taq polymerase (Fermentase), template genomic DNA 
(50–500 ng), and dH2O to 25 μl.
 (f) Amplify the miRNA gene in a thermocycler by using the fol-
lowing program: initial denaturation at 94 °C for 5 min fol-
lowed by 25 cycles for initiation at 94 °C for 1 min, annealing 
at 50 °C for 1 min, and elongation at 72 °C for 1 min. 
Fig. 1 Primer design to PCR-amplify the dme-miR7 gene. The miRNA sequence was obtained from flybase. 
Placing the mature miRNA sequence in the middle (gray-shadowed and underlined), approximately 150–200 bp 
from each region is amplified. Sequences complementary to the primer sequences are italicized and under-
lined. One of the restriction sites that does not cut the miRNA gene but is present in the multiple cloning site of 
the expression vector is then placed on each primer with a few extra nucleotide sequences (depending on the 
restriction site chosen). Such a design would result in a forward primer 5′ GGGGATCCCATCACCATCTCGGGCACGC 
3′ and a reverse primer 5′ GGGAGCTCTGTTTCGCCTGCCATTCTG 3′. The restriction sites are bolded in the 
primer sequences. The two additional 5′ G residues are used to facilitate more efficient restriction digestion
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The program is finished with a final extension at 72 °C for 
10 min. The PCR products are run on 1 % agarose gel to check 
the size of the fragment against a marker. Note that the anneal-
ing temperature depends upon the melting temperature of the 
primers, which will vary depending on the primer sequence.
 (g) The PCR-amplified fragment should be purified from agarose 
gel to eliminate contaminating genomic DNA and incomplete 
PCR products. The purelink quick gel extraction kit 
(Invitrogen) yielded consistent results in our lab. Since the 
company provides detailed instructions, this particular proce-
dure will not be explained here. It is important to keep in 
mind that elution of the fragment into distilled water increases 
the efficiency of downstream enzymatic reactions.
 (h) The PCR-amplified and gel-purified products of miRNA pre-
cursor includes adenine residues at their 3′ ends due to exten-
sion by Taq polymerase. By taking advantage of this property, 
the fragments are easily cloned into TA cloning vectors using 
the instructions of the manufacturer. We commonly use 
pGEM T easy (Promega) or pTZ57R/T (Fermentase) for this 
purpose. 50 ng vector and 4.5–5 ng extracted PCR product of 
approximately 300–500 bp is sufficient to set up an efficient 
ligation reaction. Note that the ligation reaction can be com-
pleted in 1 h or left overnight if desired.
Since blue-white colony screening is performed to select the correct 
transformant carrying the miRNA precursor, 40 μl X-Gal, and 7 μl 
IPTG should be spread onto an agar plate before starting the trans-
formation procedure. If commercial competent cells are used, we 
advise that the manufacturer’s instructions are followed. The follow-
ing procedure originally described by Sambrook and Russell [18] 
works well for home-made competent cells. Remember to prepare a 
water-bath at 42 °C before you start the transformation.
 (a) Immediately place 50 μl competent cells into an ice-cold 
Eppendorf tube and let it thaw on ice.
 (b) Gently add 5 μl ligation mixture into the competent cells and 
incubate on ice for 20 min after mixing the tube content 
gently.
 (c) Heat shock the cells at 42 °C for 45 s and immediately place 
the tube on ice for 2 min.
 (d) Add 950 μl SOC medium into the tube and shake 1 h in a 
shaker (100 RPM at 37 °C).
 (e) Spread 100 μl onto an agar plate containing the appropriate 
selectable antibiotic. Incubate the plate in an incubator at 
37 °C overnight (16–24 h).
3.1.2 Transformation  
of Ligation Products to 
DH5α Competent Cells
[AU1]
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 (f) A single white colony is then streaked onto an agar plate again 
to obtain a pure single colony. One of the colonies is inoculated 
into 8 ml LB medium and the plasmid is purified via a plasmid 
purification kit (e.g., Fermentase GeneJET™ plasmid miniprep 
kit K0503) according to the manufacturer’s instructions.
The fragment containing the miRNA precursor sequence is released 
from the sub-cloning vector by digesting it with the appropriate 
restriction enzymes (e.g., 5′ BamHI and 3′ SalI). The expression 
vector is also digested by the same enzymes to generate sticky ends 
for the ligation of the miRNA precursor released from the sub- 
cloning vector. The last step involves ligating the miRNA-carrying 
fragment into the expression vector with the sticky ends. The basic 
molecular biology protocols described by Sambrook and Russell 
[18] can be used to complete this step. Two control reactions 
should be included to minimize the number of false-positive trans-
formants. Control ligation I is basically the same as the test reac-
tion but does not contain any ligase enzyme. Control ligation II 
should not contain any insert. When transformed into E. coli, no 
transformants should be observed from these two control ligation 
reactions if the expression vector is prepared properly. Following 
the transformation, the cloning efficiency can be checked as in 
Subheading 3.1.2.
The chimeric gene includes firefly luciferase gene whose 3′UTR is 
replaced with that of the miRNA target which contains a single or 
multiple binding sites for the miRNA of interest. This chimera is 
cloned into an expression vector (e.g., pAct-5c for expression in 
Drosophila S2 cells) to examine the effect of miRNA:target 3′UTR 
interaction on the expression of the reporter luciferase activity.
 (a) Forward and reverse primers are designed as in Subheading 
3.1.1, step a to amplify firefly luciferase without its 3′UTR. 
The selected restriction sites should be present in the correct 
orientation in the expression vector. The pGL4.12[luc2CP] 
construct can be used as a template to amplify firefly luciferase 
as in Subheading 3.1.1. The only difference is that the template 
DNA is pGL4.12 for this reaction.
 (b) Double-digest the expression vector pAct-5c and the PCR 
products with the same restriction enzymes included in the 
primers to amplify the firefly luciferase and extract from 1 % 
agarose gel by a fragment isolation kit.
 (c) Ligation, transformation, and verification of the insert can be 
performed as in Subheading 3.1.
 (d) Steps 3.2a–d are repeated but with a pair of primers comple-
mentary to the 3′UTR of target mRNA to insert the 3′UTR 
of the miRNA target downstream from the firefly luciferase.
3.1.3 Transfer of the 
MicroRNA Precursor from 
the Cloning Vector into an 
Expression Vector
3.2 Construction  
of a Chimeric Gene 
Carrying the Open 
Reading Frame of the 
Luciferase Firefly Gene 
Fused to the 3′UTR of 
a Target mRNA
[AU2]
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It is important to normalize the transfection efficiency in all transfection 
reactions. This is accomplished by transfecting the cells with a different 
reporter gene such as luciferase renilla. The cloning rationale is almost 
the same as in Subheading 3.1 except for the template and the pair of 
primers. The commercial plasmid pGL4.74(hRluc/TK, Promega) is 
used as a template instead.
 (a) 24 h before transfection, Drosophila S2 cells (5 × 105 per well) 
are seeded in a 6-well plate (Jet Biofil, TCP011006) in com-
plete medium containing 10 % FBS and 2 % Penicillin–
Streptomycin (At least four wells should be seeded to measure 
one miRNA-target dual reporter assay—referred to as well 1, 2, 
3, and 4). Well 1 contains the control S2 cells that are not trans-
fected with any plasmids. It is used to assess the effect of the 
transfection reagent on S2 cells. Well 2 is another control that 
is used for transfection with the empty expression vector (pAct-
 5c) to measure the effect of plasmids, if any, to the cells. Well 3 
contains S2 cells transfected with the chimeric reporter gene 
(firefly luciferase and target mRNA 3′UTR). Well 4 contains 
the S2 cells transfected with the miRNA expression plasmid 
(e.g., pAct-5c-miRX) and the chimeric reporter gene. The cells 
in the wells 2, 3, and 4 are also transfected with equal amounts 
of renilla luciferase to normalize the transfection efficiency.
 (b) For transfection, the calcium-phosphate transfection kit 
(Invitrogen) offers high transfection rate, and 10 μg plasmid 
DNA is sufficient. It is very important to use a Pasteur pipette 
to slowly add the solutions A2, A3, and A4 (dropwise) to the 
solutions B2, B3, and B4, respectively, while bubbling air 
through by another Pasteur pipette. This is a slow process 
 executed over 1 or 2 min.
The manufacturer company’s instructions were followed to mea-
sure the luciferase activity. The measurement consists of three main 
steps: (1) cell lysis, (2) measurements of luciferase firefly, and (3) 
luciferase renilla.
 (a) 48 h after transfection, the cell medium in the wells is removed 
and cells are rinsed with 1× PBS at least twice. The rinsing 
solution should be removed completely.
 (b) 500 μl PLB is added into each well and the cell culture plate is 
placed on an orbital shaker (~50 RPM) for 15 min at room 
temperature. If desired, cells are scraped in PLB directly and 
rinsed with 1× PBS in microfuge tubes. 500 μl PLB is added 
and cells are lysed by pipetting.
 (c) Luciferase reporter function can be conveniently measured in a 
96-well plate using a luminometer (VarioScan, Thermo). The 
luminometer is programmed to read a 2-s premeasurement 
delay followed by a 10-s measurement period for each reporter 
assay. 20 μl cell lysate is usually sufficient for each assay.
3.3 Construction  
of the Normalization 
Vector Containing 
Renilla Luciferase
3.4 S2 Cell 
Transfection
3.5 Measurement  
of Luciferase Reporter 
Function
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 (d) Cells may possess very little amount of luciferase. Thus, the 
background enzymatic activity should be subtracted from the 
total luminescence. For this purpose, non-transfected control 
cells are lysed in PLB and used as a negative control. Any lumi-
nescence obtained from this sample is subtracted from all other 
readings.
4 Conclusion
Advances in sequencing technology have nearly exhausted the 
identification of potential miRNAs in mammals. Nowadays, it has 
become more important to identify potential targets of miRNAs 
and to understand the significance of miRNA:mRNA interactions 
in biological systems. Although sophisticated target prediction 
algorithms effectively predict miRNA–mRNA interactions, experi-
mental validation is essential in animals due to imperfect pairing 
between miRNAs and their targets.
Typically, transcriptome analyses, biochemical approaches, and 
proteome analyses are used to identify miRNA:mRNA interac-
tions. Gene reporter assays are preferred over other approaches as 
they nicely avoid off-target effects associated with transcriptome or 
proteome analyses. Direct demonstration of a single miRNA:mRNA 
interaction increases specificity. Reporter assays are also attractive 
due to their simplicity and cost-effectiveness.
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